ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1743

What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Abstract Number: 2519

What Do We Know About Malignancies in IgA Vasculitis?
Abstract Number: 0557

What Factors Are Associated with Pain Intensity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)
Abstract Number: 0360

What Happens in Rheumatoid Arthritis Treatment Adherence, Two Years After the Introduction of Targeted Therapy? Results from the STRATEGE2 Study
Abstract Number: 1298

What Is an ANA and Why Should I Care? Strategies to Increase Understanding of Basic Rheumatologic Labs Within Medical Education
Abstract Number: 0995

What Is the Carbon Footprint of Adalimumab Originator and Its Various Biosimilar Drugs?
Abstract Number: 1756

What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor
Abstract Number: 1339

When Medications Fail: A Mixed Methods Study Evaluating the Experience and Health-Related Quality of Life (HRQOL) of Adults with Rheumatoid Arthritis Non-Responsive to Treatment
Abstract Number: 2675

Which Arthralgia Patients at Risk for RA Benefited from Treatment with Methotrexate?; Results from the TREAT EARLIER Trial
Abstract Number: 1326

Which Biomarkers Indicate Imminent Progression to Inflammatory Arthritis in High Risk CCP Positive Persons?
Abstract Number: 0259

Whipple’s Disease in Patients Initially Diagnosed with Rheumatic Diseases: A Case Series
Abstract Number: PP08

Whispers of Resilience: Navigating Life with Rheumatism
Abstract Number: 2200

Whole Blood Transcriptome Profiling in Juvenile Systemic Sclerosis Patients Reveals Active Immune Upregulation and Enhanced Fibrotic Signature
Abstract Number: 1589

Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis
Abstract Number: 1277

Why Did You Choose That Score? – Associations Between Patient Global Assessment Scores and Mental Health in Patients with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].